reports
Press Release: Sanofi initiates phase 3 program for PCV21 and expands ...
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines Pneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter phase 3 in infants & toddlers Paris, December ...
Communiqué de presse : Sanofi lance un programme de phase III pour son...
Communiqué de presse : Sanofi lance un programme de phase III pour son vaccin VPC21 et élargit sa collaboration avec SK Bioscience afin de développer une nouvelle génération de vaccins pneumococciques conjugués Sanofi lance un programme de phase III pour son vaccin VPC21 et élargit sa collaboration avec SK Bioscience afin de développer une nouvelle génération de vaccins pneumococciques conjugués Les infections à pneumocoques demeurent un enjeu majeur de santé publique malgré les vaccins actuellement disponibles. Ce vaccin pneumococcique conjugué 21-valent (VPC21) est le premier candidat-...
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024. Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025, replacing Gilles Schnepp who has decided to leave the Board at the end of 2024. Jean-Paul Kress will hold his position for the remainder of Gilles Schnepp's term of office and his appointment will be subject to ratification at the next Ordinary Shareholders' Meeting of Sanofi. Jean-Paul Kress, M.D., served as the CEO of MorphoS...
Communiqué de presse - Jean-Paul Kress rejoint le Conseil d’administra...
Communiqué de presse - Jean-Paul Kress rejoint le Conseil d’administration de Sanofi Jean-Paul Kress rejoint le Conseil d’administration de Sanofi Paris, le 19 décembre 2024. Le Conseil d’administration de Sanofi est heureux d’accueillir Jean-Paul Kress en qualité d’administrateur indépendant à compter du 1er janvier 2025, en remplacement de Gilles Schnepp qui a décidé de quitter le conseil à la fin de l’année 2024. Jean-Paul Kress exercera ses fonctions pour la durée restant à courir du mandat de Gilles Schnepp et sa nomination sera soumise à la ratification de la prochaine Assemblée Géné...
- Emna Ben Bdira
- Maxime Kogge
MT ARCELORMITTAL SA
CA CARREFOUR SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
RNO RENAULT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
SZG SALZGITTER AG
VOE VOESTALPINE AG
ACX ACERINOX SA
SAN SANOFI
ERA ERAMET SA
NDA AURUBIS AG
FTON FEINTOOL INTERNATIONAL HOLDING AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
BHP BHP GROUP LTD
- Emna Ben Bdira
- Maxime Kogge
MT ARCELORMITTAL SA
CA CARREFOUR SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
RNO RENAULT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
SZG SALZGITTER AG
VOE VOESTALPINE AG
ACX ACERINOX SA
SAN SANOFI
ERA ERAMET SA
NDA AURUBIS AG
FTON FEINTOOL INTERNATIONAL HOLDING AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
BHP BHP GROUP LTD
- Damien Choplain
- Martial Descoutures
- Damien Choplain
- Martial Descoutures
Press Release: Duvakitug positive phase 2b results demonstrate best-in...
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibodySanofi and Teva plan to initiate phase 3 development in IBD, pending regulatory discussionsProgram under...
Communiqué de presse : Les résultats positifs de phase IIb concernant ...
Communiqué de presse : Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn Les résultats positifs de phase IIb concernant le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn Les critères d’évaluation primaires ont été satisfaits pour la colite ulcéreuse et la maladie de Crohn, les deux formes les plus courantes de maladies inflammatoires de l’intestin (MII) .Le...
Press Release: Availability of the Q4 2024 Aide-mémoire
Press Release: Availability of the Q4 2024 Aide-mémoire Availability of the Q4 2024 Aide-mémoire Paris, France – December 17, 2024. Sanofi announced today that its Q4 2024 Aide-mémoire is available on the "Investors" page of the company's website: As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's fourth quarter & full year 2024 results will be published on January ...
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA...
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS)Tolebrutinib is the first and only brain-penetrant BTK inhibitor in MS to be designated Breakthrough Therapy by the FDA Paris, December 13, 2024. The US Food and Drug Administration (FDA) has granted Breakt...
Communiqué de presse : Le tolebrutinib obtient la désignation de « Méd...
Communiqué de presse : Le tolebrutinib obtient la désignation de « Médicament innovant » de la FDA pour le traitement de la sclérose en plaques secondairement progressive sans poussées Le tolebrutinib obtient la désignation de « Médicament innovant » de la FDA pour le traitement de la sclérose en plaques secondairement progressive sans poussées Désignation motivée par les résultats positifs de l’étude HERCULES chez l’adulte porteur d’une sclérose en plaques secondairement progressive (SEP-SP) sans poussées.Le tolebrutinib est le premier et le seul inhibiteur de la BTK à pénétration cérébr...
- Emira Sagaama
- Ghada Ben Sedrine
- Nicolas David
- Oddo Sustainability Team
- Thomas Zlowodzki
SOP SOPRA STERIA GROUP SA
ATO ATOS SE
ROG ROCHE HOLDING LTD
ACN ACCENTURE PLC CLASS A
NOVN NOVARTIS AG
LONN LONZA GROUP AG
INF INFOTEL SA
SQI SQLI SA
SWP SWORD GROUP SE
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
AUB AUBAY SA
ATE ALTEN SA
ZAL ZALANDO SE
GRF GRIFOLS S.A. CLASS A
SAN SANOFI
CAP CAPGEMINI SE
TLX TALANX AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
ITX INDUSTRIA DE DISENO TEXTIL S.A.
BC BRUNELLO CUCINELLI S.P.A.
IDR INDRA SISTEMAS S.A. CLASS A
GRF.P GRIFOLS S.A. PREF CLASS B
AZN ASTRAZENECA PLC
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
ALG ALLEGRO.EU SA
NA9 NAGARRO
EXN EXCLUSIVE NETWORKS SA
GSK GSK PLC
IOS IONOS GROUP SE
NOVO B NOVO NORDISK A/S
- Emira Sagaama
- Ghada Ben Sedrine
- Nicolas David
- Oddo Sustainability Team
- Thomas Zlowodzki
SOP SOPRA STERIA GROUP SA
ATO ATOS SE
ROG ROCHE HOLDING LTD
ACN ACCENTURE PLC CLASS A
NOVN NOVARTIS AG
LONN LONZA GROUP AG
INF INFOTEL SA
SQI SQLI SA
SWP SWORD GROUP SE
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
AUB AUBAY SA
ATE ALTEN SA
ZAL ZALANDO SE
GRF GRIFOLS S.A. CLASS A
SAN SANOFI
CAP CAPGEMINI SE
TLX TALANX AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
ITX INDUSTRIA DE DISENO TEXTIL S.A.
BC BRUNELLO CUCINELLI S.P.A.
IDR INDRA SISTEMAS S.A. CLASS A
GRF.P GRIFOLS S.A. PREF CLASS B
AZN ASTRAZENECA PLC
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
ALG ALLEGRO.EU SA
NA9 NAGARRO
EXN EXCLUSIVE NETWORKS SA
GSK GSK PLC
IOS IONOS GROUP SE
NOVO B NOVO NORDISK A/S
- Team Pharma
- Team Pharma
Press Release: Two combination vaccine candidates for prevention of in...
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US First non-mRNA combination vaccine candidates that include two already licensed vaccines to prevent influenza and COVID-19 infectionsTwo phase 1/2 clinical studies are ongoing to evaluate the safety profile and immune response induced by the combination vaccine candidates Paris, December 11, 2024. The US Food and Drug Administration has grante...
Press Release: ASH: Sarclisa combinations demonstrated significant ben...
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained MRD negativity rates in transplant-ineligible NDMM patients versus VRd aloneNew detailed results from the GMMG-HD7 phase 3 study of Sarclisa-RVd induction therapy resulted in a significant and clinically meaningful PFS benefit with deeper MRD negativity in transplant-eligibl...
Communiqué de presse : ASH : les associations thérapeutiques avec Sarc...
Communiqué de presse : ASH : les associations thérapeutiques avec Sarclisa procurent des bénéfices significatifs aux patients atteints d’un myélome multiple nouvellement diagnostiqué ASH : les associations thérapeutiques avec Sarclisa procurent des bénéfices significatifs aux patients atteints d’un myélome multiple nouvellement diagnostiqué Une nouvelle analyse des données de l’étude de phase III IMROZ associant le Sarclisa au schéma VRd a permis d’obtenir un taux supérieur et soutenu de négativité de la MRD chez des patients atteints d’un MMND, non éligibles à une greffe, comparativemen...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.